Item 5. OTHER INFORMATION

Rule 10b5-1 Plans

On April 28, 2023, Gary S. Guthart, Ph.D., the Company’s Chief Executive Officer and a member of the Company’s Board of Directors, adopted a Rule 10b5-1 trading plan. Dr. Guthart’s trading plan provides for (i) the potential exercises of vested stock options to purchase up to 135,000 shares of the Company’s common stock, (ii) the potential sales of shares of the Company’s common stock received upon such exercises to cover exercise costs, estimated tax withholding amounts, and customary brokerage fees as well as potential additional sales of such shares, (iii) the potential donation of 16,000 shares of the Company’s common stock from a trust in which Dr. Guthart is a trustee, and (iv) the potential sales of up to 14,880 shares of the Company’s common stock held by trusts in which the beneficiaries are children of Dr. Guthart, until April 29, 2024. This trading plan was entered into during an open insider trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Company’s policies regarding transactions in the Company’s securities.

On May 1, 2023, Amal M. Johnson, a member of the Company’s Board of Directors, adopted a Rule 10b5-1 trading plan. Ms. Johnson’s trading plan provides for the potential exercise and sale of up to 16,263 shares of the Company’s common stock subject to an option until May 1, 2024. This trading plan was entered into during an open insider trading window and is

intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and the Company’s policies regarding transactions in the Company’s securities.

On May 3, 2023, Jamie E. Samath, the Company’s Chief Financial Officer, adopted a Rule 10b5-1 trading plan. Mr. Samath’s trading plan provides for the potential sale of up to 19,887 shares of the Company’s common stock, including the potential exercise and sale of up to 13,870 shares of the Company’s common stock subject to stock options, until May 3, 2024. This trading plan was entered into during an open insider trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and the Company’s policies regarding transactions in the Company’s securities.

On May 8, 2023, Alan J. Levy, Ph.D., a member of the Company’s Board of Directors, adopted a Rule 10b5-1 trading plan. Mr. Levy’s trading plan provides for the potential exercise and sale of up to 8,000 shares of the Company’s common stock subject to stock options until May 8, 2024. This trading plan was entered into during an open insider trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and the Company’s policies regarding transactions in the Company’s securities.

On June 15, 2023, Amy L. Ladd, M.D., a member of the Company’s Board of Directors, adopted a Rule 10b5-1 trading plan. Ms. Ladd’s trading plan provides for the potential sale of up to 500 shares of the Company’s common stock until June 14, 2024. This trading plan was entered into during an open insider trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and the Company’s policies regarding transactions in the Company’s securities.